IBM’s Watson supercomputer leading charge into early melanoma detection

IBM is breaking ground in the early detection of skin cancer using its supercomputer Watson, potentially saving the federal government hundreds of millions of dollars.

Biocartis Group NV: Study using Biocartis’ liquid biopsy BRAF assay shows new option for retreatment of melanoma patients

Mechelen, Belgium, 9 March 2017 – Biocartis Group NV (‘Biocartis’ or ‘the Company’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication in the renowned clinical oncology journal The Lancet Oncology of an important study by Prof. Dr. Bart Neyns from the University Hospital in Brussels (Belgium).

Binimetinib Improves PFS in NRAS-mutant Melanoma

Source: Cancer Therapy Advisor, March 2017 Binimetinib significantly prolonged progression-free survival compared with dacarbazine and was associated with a manageable safety profile among patients with advanced, NRAS-mutant melanoma, according to a study published in The Lancet Oncology.1 For the ongoing, international, open-label, phase 3 NEMO trial ( Identifier: NCT01763164), researchers evaluated the efficacy and safety […]

Melanoma marathon to raise money against deadly disease

A FORMER truck driver, who has battled melanoma and won, is taking on perhaps his biggest challenge yet in a bid to save others from the deadly disease.

Cancer in the News

Feature Articles

Array BioPharma And Columbus’s Egg

In my first articles as a Seeking Alpha contributor, I’ve highlighted the potential of three widely differing companies: Bristol-Myers Squibb (NYSE:BMY), Tracon (NASDAQ:TCON) and Innate Pharma (OTCPK:IPHYF).

Read the full story

Posted in Melanoma In The News, Other Melanoma Research

COMBI-v BRAF/MEK Inhibitor Combination Trial Continues to Impress in Melanoma

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Rare Cardiotoxicity Effects Founds With Checkpoint Inhibitors in Melanoma

As the oncology community adapts to using immunotherapy agents more frequently in cancer treatments, the fear over immune-related adverse events (irAEs) prevents many clinicians from fully trusting immunotherapies.

Read the full story

Posted in Melanoma In The News

Mutations in ATR Gene Promote Melanoma Tumor Growth

Investigators identified a mechanism used by melanoma cells to modulate the immune microenvironment to promote continued growth, according to a study.

Read the full story

Posted in Melanoma In The News, Other Melanoma Research

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories